This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study sample
A total of 2,780 patients were included in the study. Of these, 1,425 were allocated to the control group, and 1,355 were allocated to the WBC-reduced blood group. All patients who received blood products, and were not excluded for the clinical reasons detailed above, were included in the study. Informed consent was not sought and the patients were not told they were in a trial. The authors undertook sample size calculations. These indicated that a sample of 1,312 in each treatment group was required to have an 85% chance of detecting a 15% difference in post transfusion length of hospital stay with 95% confidence (two-sided).
Study design
The study was a randomised controlled trial that was conducted in a single centre. The patients were randomised to either the intervention or control group on the basis of their unique hospital number, which are consecutively allocated to patients on their first admission to the hospital. The allocation of hospital numbers is an administrative process that cannot be influenced by any individual involved in patient care. The patients were followed up for the duration of their hospital stay. There was no loss to follow-up as the data were collected from medical records. Clinical staff, patients and their carers were unaware that the study was taking place, and were therefore blind to the type of blood products received by the patient.
Analysis of effectiveness
The primary health outcomes assessed by the study were the length of hospital stay and in-hospital mortality. The primary analysis was undertaken on an intention to treat basis. The two patient groups were comparable in terms of gender, age, whether they were undergoing surgery and type of surgery, primary diagnosis, distribution of volumes of blood transfused, and the number of patients who received blood that did not match with their study allocation.
Effectiveness results
In-hospital mortality was 9.0% in the WBC-reduced group versus 8.5% in the control group (odds ratio, OR=0.94, 95% confidence interval, CI: 0.72 -1.22; p=0.64).
The median length of stay after transfusion was 6.3 days in the WBC-reduced group versus 6.4 days in the control group, (p=0.21).
The median total length of stay was 8.8 days in the WBC-reduced group and 8.9 days in the control group.
Clinical conclusions
The authors concluded that there was no difference in clinical outcomes between the use of WBC-reduced blood and non WBC-reduced blood.
Measure of benefits used in the economic analysis
No summary measure of benefit was used in the economic analysis. In effect, a cost-consequences analysis was undertaken.
Direct costs
This study assesses the costs to the hospital. The quantities and costs of all resources used, except the cost of processing the WBC-reduced blood products, were taken from the hospital's cost manager database. The authors assessed the cost of processing the WBC-reduced products to be $30 per dose. The quantities and unit costs of the resources used were not reported, nor was the price year. No discounting was undertaken since the duration of the study was less than one year.
